Drugs / MCV4
MCV4
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00459316 | Jun 2007 → Mar 2013 | HIV infectious disease, bacterial meningitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06700148 | Dec 2024 → Aug 2025 overdue | meningococcal meningitis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06226714 | Mar → Sep 2024 overdue | meningococcal meningitis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06011200 | Sep → Dec 2023 | meningococcal meningitis | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06389513 | Jun 2024 → Dec 2025 overdue | infectious meningitis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05935176 | Sep 2023 → May 2026 overdue | meningoencephalitis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07203755 Comparator | Dec 2025 → Feb 2029 expected | haemophilus infectious disease, meningitis | CanSino Biologics Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01461980 Comparator | Sep 2011 → May 2014 | meningococcal infection | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCV4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06226714 ↗ |
| Known as | ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) | “ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)” NCT06226714 ↗ |
| Known as | Meningococcal Group ACYW135 (Conjugate) (MCV4) | “Meningococcal Group ACYW135 (Conjugate) (MCV4)” NCT07203755 ↗ |
| Known as | Quadrivalent meningococcal conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00459316 ↗ |
| Modality | Vaccine | “The quadrivalent meningococcal conjugate vaccine (MCV4) is a vaccine” NCT00459316 ↗ |
| Route | Intramuscular | “was given by injection intramuscularly” NCT00459316 ↗ |